Economic evaluation of aclidinium bromide in the management of moderate to severe COPD: an analysis over 5 years
Andreas Karabis,1 Michelle Mocarski,2 Indra Eijgelshoven,1 Gert Bergman1 1Mapi HEOR and Strategic Market Access, Houten, the Netherlands; 2Forest Research Institute, Jersey City, NJ, USA Purpose: Aclidinium bromide is a long-acting muscarinic antagonistic used in maintenance treatment of chronic obs...
Saved in:
Main Authors: | Karabis A (Author), Mocarski M (Author), Eijgelshoven I (Author), Bergman G (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2014-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cost versus utility of aclidinium bromide 400 μg plus formoterol fumarate dihydrate 12 μg compared to aclidinium bromide 400 μg alone in the management of moderate-to-severe COPD
by: Ramos M, et al.
Published: (2016) -
Aclidinium bromide/formoterol fixed-dose combination therapy for COPD: the evidence to date
by: Moitra S, et al.
Published: (2015) -
Clinical potential of aclidinium bromide in chronic obstructive pulmonary disease
by: Zhong J, et al.
Published: (2014) -
New combinations in the treatment of COPD: rationale for aclidinium–formoterol
by: Incorvaia C, et al.
Published: (2016) -
Role of once-daily glycopyrronium bromide (NVA237) in the management of COPD
by: D’Urzo A
Published: (2013)